Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Director | January 26, 2026 | January 28, 2026 |
| Dogwood Therapeutics, Inc.DWTX · Entity 6845 | Director · CHIEF EXECUTIVE OFFICER | March 05, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date January 26, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,786 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 30,453 · Balance 68,786 F1: These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.
Dogwood Therapeutics, Inc.
Report date March 05, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.86 · Expires 2036-03-05 | Direct | 330,000 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 330,000 · Balance 330,000 F1: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 6, 2026 21:16 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001831127-26-000005 · form4-03062026_090335.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2036-03-05 F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 30,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-008472 · ownership.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,786 F1 · price: These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:05 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001831127-25-000005 · form4-12052025_041207.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2035-12-04 F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 13,333 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001213900-25-089216 · ownership.xml · derivative · entry 2 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 13,333 shares Expires 2031-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were granted on 1/11/2021. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 13,333 | $8.32 | $110,930.56 |
DisclosureSEC source: 0001213900-25-089216 · ownership.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 18:00 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001415889-25-018643 · form4-07012025_060730.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-27 F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter. Read SEC document |
| January 17, 2025 Filed Jan 23, 2025 02:04 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-005667 · ownership.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: These shares represent restricted stock units issued on January 17, 2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 17, 2026, subject to continued service on the vesting date. Read SEC document |
| March 05, 2024 Filed Mar 20, 2024 20:22 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899140-24-000321 · form4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: These options were granted on 3/5/2024. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 17:40 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 138,835 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-24-005666 · form4-02282024_050227.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,835 Underlying: Common Stock · 138,835 shares Expires 2034-02-26 F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 11:05 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 25,000 | $1.25 | $31,245.00 |
DisclosureSEC source: 0001415889-23-012375 · form4-08182023_070801.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,461 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.00 to $1.25, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 23:56 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003549 · ownership.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:33 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 480,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012561 · form4-12142022_111237.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| December 12, 2022 Filed Feb 15, 2023 17:54 UTC Amendment | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-23-002583 · form4a-02152023_050206.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2032-12-12 F1 · shares: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. F2 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. F1 · derivative.underlying_shares: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. F1 · balance_after: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:38 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007076 · form4-06302022_100647.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| May 23, 2022 Filed May 24, 2022 14:24 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 7,500 | $4.52 | $33,900.00 |
DisclosureSEC source: 0001415889-22-005567 · form4-05242022_070548.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,461 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:23 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008962 · doc4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F4 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 18:23 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 5,000 | $5.52 | $27,615.00 |
DisclosureSEC source: 0001415889-21-006172 · form4-12222021_101249.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,961 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.395 to $5.708, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 20:58 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-21-003142 · form4-06222021_010611.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 17:59 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 382 | $6.36 | $2,428.60 |
DisclosureSEC source: 0001104659-21-047486 · tm2112418-1_4seq1.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 01:56 UTC Amendment | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 15,675 | $6.17 | $96,757.07 |
DisclosureSEC source: 0001104659-21-047253 · tm2112349d1_4a.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,579 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 19:38 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 15,675 | $6.17 | $96,757.07 |
DisclosureSEC source: 0001104659-21-047069 · tm2112297-1_4.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,579 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 00:45 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 21,796 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003576 · tm212264-5_4seq1.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,921 Underlying: Common Stock · 21,796 shares Expires 2030-12-21 F1 · kind: Stock options granted pursuant to the reporting person's employment agreement. Pursuant to that employment agreement, the reporting person was entitled to receive a total of 435,921 stock options. In error, the Issuer previously granted only 414,125. This grant was made solely to correct the error in the number of stock options granted under the reporting person's employment agreement. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:19 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001213900-21-002062 · doc4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: These options were granted on 1/11/2021. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:23 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 801 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-002579 · tm212264-1_4seq1.xml · derivative · entry 2 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 801 shares Expires 2021-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:23 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionCommon Stock | 801 | $7.80 | $6,247.80 |
DisclosureSEC source: 0001104659-21-002579 · tm212264-1_4seq1.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 01:12 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 414,125 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138202 · tm2039099-4_4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,125 Underlying: Common Stock · 414,125 shares Expires 2030-12-21 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:06 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 2,500 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-20-035045 · doc4.xml · derivative · entry 2 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2030-11-02 F2 · derivative.exercise_date: These options were granted on 11/02/2020 and are subject to monthly vesting in equal installments during the one-year period beginning on December 2, 2020, subject to continued service on the board. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:06 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-20-035045 · doc4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-02 F1 · derivative.exercise_date: These options were granted on 11/02/2020. One-third of the options vested on the date of grant. One-third of the options will vest on each of the first and second anniversaries of the date of grant, subject to continued service on the board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.